## Daniele Altomare

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8093708/publications.pdf Version: 2024-02-01



DANIELE ALTOMADE

#	Article	IF	CITATIONS
1	Description of a European memory clinic cohort undergoing amyloidâ€PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.8	6
2	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
3	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	10.2	203
4	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.8	24
5	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2200-2211.	6.4	19
6	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	6.4	18
7	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. Alzheimer's Research and Therapy, 2021, 13, 105.	6.2	15
8	Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services—part 6 of 6. Alzheimer's Research and Therapy, 2021, 13, 173.	6.2	14
9	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
10	Dementia risk communication. A user manual for Brain Health Services—part 3 of 6. Alzheimer's Research and Therapy, 2021, 13, 170.	6.2	21
11	Protocols for cognitive enhancement. A user manual for Brain Health Services—part 5 of 6. Alzheimer's Research and Therapy, 2021, 13, 172.	6.2	15
12	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6. Alzheimer's Research and Therapy, 2021, 13, 168.	6.2	26
13	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171.	6.2	37
14	Towards fingerprinting and identifiability within the Alzheimer's continuum using restingâ€state functional connectivity. Alzheimer's and Dementia, 2021, 17, .	0.8	0
15	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	6.4	23
16	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.1	55
17	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of diseaseâ€modifying therapies. Alzheimer's and Dementia, 2020, 16, 1457-1468.	0.8	43
18	Impact of the disclosure of amyloidâ€PET results to patients with subjective cognitive decline: the AMYPAD Diagnostic and Patient Management Study (DPMS). Alzheimer's and Dementia, 2020, 16, e040952.	0.8	0

DANIELE ALTOMARE

#	Article	IF	CITATIONS
19	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. Alzheimer's and Dementia, 2020, 16, e042628.	0.8	1
20	Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): Retrospective analyses on the Geneva Memory Clinic cohort. Alzheimer's and Dementia, 2020, 16, e045436.	0.8	1
21	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
22	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 414-421.	0.7	5
23	IS A LARGE-SCALE SCREENING FOR ALZHEIMER'S DISEASE POSSIBLE? YES, IN A FEW YEARS. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-2.	2.7	3
24	Medial temporal lobe atrophy and posterior atrophy scales normative values. NeuroImage: Clinical, 2019, 24, 101936.	2.7	12
25	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	3.6	11
26	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.1	51
27	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
28	Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloidâ€₽ET. Alzheimer's and Dementia, 2018, 14, 1088-1098.	0.8	15
29	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1557-1566.	6.4	35
30	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486.	6.4	19
31	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1546-1556.	6.4	24
32	Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	6.4	61
33	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1534-1545.	6.4	86
34	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1487-1496.	6.4	35
35	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain <sup>18</sup> Fâ€fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology. 2018. 25. 1201-1217.	3.3	153
36	Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation. Journal of Alzheimer's Disease, 2018, 65, 221-230.	2.6	44

DANIELE ALTOMARE

#	Article	IF	CITATIONS
37	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1509-1525.	6.4	81
38	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1526-1533.	6.4	28
39	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. JAMA Neurology, 2016, 73, 1417.	9.0	84
40	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?. Neurodegenerative Diseases, 2016, 16, 111-117.	1.4	6
41	Brain atrophy in Alzheimer's Disease and aging. Ageing Research Reviews, 2016, 30, 25-48.	10.9	507